TNF and Cowden disease: At present, biological agents that specifically inhibit TNF-α have been widely used in the induction and maintenance treatment of patients with moderate to severe CD after the failure of conventional treatment and are recommended as first-line biological therapy by the American College of Gastroenterology (ACG) guidelines, the European Organization for Crohn’s Disease and Colitis (ECCO) guidelines and other authoritative guidelines worldwide.